Clinton Transition Co-Chair Tanden Offers Themes For A Drug Pricing Bill In 2017
Executive Summary
FAIR Drug Pricing Act, CAP proposal and Collins bill include viable legislative movers for next administration. CMS Acting Administrator Slavitt signals that Part B demo will move forward based on CBO score.
You may also be interested in...
‘March In’ Plan Unveiled By Democratic Think Tank: A Battle Biopharma Would Welcome?
In sign of how much has changed in four years, industry might be better off if Biden takes CAP’s advice and launches ‘march-in’ actions to address pricing of COVID products.
Biopharma Goes 3 For 3 In Presidential Debates
The Presidential debates are over, and the biopharmaceutical industry has to be counted among the winners, simply because there was no substantive discussion of high drug prices as an issue. That may not mean much come 2017 – but at least the industry’s reputation hasn’t been further damaged during the highest profile phase of the national campaign.
Part B Demo Could Save $2.2 Bil., CBO Says; Blocking It Would Cost Less
CMS’ proposal to test alternate payment methods for Part B drugs could save as much as $2.2 billion over 10 years, the Congressional Budget Office told Congress. However, a bill to block implementation of the program would only cost $395 million for scoring purposes.